Sanofi (SNY) Reports Q4 Revenues of EUR9.61B
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Drugmaker Sanofi expects further profit growth from narrowed focus
February 6, 2020 1:51 AM ESTBy Matthias Blamont
PARIS (Reuters) - French drugmaker Sanofi on Thursday forecast further profit growth for 2020 even as it drops some research in areas such as diabetes in a shake-up to narrow its focus on blockbuster treatments including eczema medicine Dupixent.
Sanofi, long viewed as a laggard in the pharmaceutical sector, has changed its chief executive, its chief financial officer and head of research over the past two years and is hoping to shine again thanks to the pipeline shake-up and cost cuts.
The company... More
Sanofi investigated over epilepsy drug linked to birth defects
February 4, 2020 2:07 AM ESTPARIS (Reuters) - French drugmaker Sanofi said on Tuesday it was being investigated over Depakine, an epilepsy drug which caused birth malfunctions and slow neurological development when taken during pregnancy.
The Paris prosecutor had already launched a preliminary investigation into the authorization and marketing of Depakine in 2016, after France's social affairs inspection agency IGAS criticized the slow response of health authorities and Sanofi to the risks related to the drug and its derivatives.
Sanofi said in a statement that the indictment, which may or may not lead to a... More
